Associations - MYD88 mutation

MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials	zanubrutinib Sensitive: B - Late Trials
MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C3 – Early Trials	ibrutinib Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Marginal Zone Lymphoma Marginal Zone Lymphoma	MYD88 mutation MYD88 mutation	Marginal Zone Lymphoma Marginal Zone Lymphoma	ibrutinib Sensitive: C3 – Early Trials	ibrutinib Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials	ibrutinib Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials	methotrexate Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Marginal Zone Lymphoma Marginal Zone Lymphoma	MYD88 mutation MYD88 mutation	Marginal Zone Lymphoma Marginal Zone Lymphoma	zanubrutinib Sensitive: C3 – Early Trials	zanubrutinib Sensitive: C3 – Early Trials
MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	MYD88 mutation MYD88 mutation	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	rituximab Sensitive: C4 – Case Studies	rituximab Sensitive: C4 – Case Studies
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	BTK inhibitor + KT-413 Sensitive: D – Preclinical	BTK inhibitor + KT-413 Sensitive: D – Preclinical
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab + KT-413 Sensitive: D – Preclinical	rituximab + KT-413 Sensitive: D – Preclinical
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical	KT-413 Sensitive: D – Preclinical